Aspire Biopharma Holdings, Inc. (ASBP)Healthcare | Biotechnology | Estero, United States | NasdaqCM
8.51 USD
+0.22
(2.654%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 8.51 |
Hot Take ↕ | Aug. 22, 2026, 1:12 a.m. EDT
The immediate outlook is neutral-to-slightly-bearish due to a severe disconnect between the current trading price and the company's book value, compounded by a massive 95% crash over the last fiscal year. While the stock recently stabilized near its historical book value per share, the underlying business fundamentals are catastrophic: the company reports negative gross margins, negative operating margins, and negative earnings per share, indicating a failing operational model rather than a distressed opportunity. The recent news of a reverse stock split and a pivot into caffeine sticks suggests a desperate attempt to rebrand or find a niche, but this does not offset the structural damage evident in the financials. There is no dividend to provide income, and the lack of analyst coverage leaves the stock without institutional validation. The statistical forecast model shows a slight upward bias, but its extremely low reliability score renders it useless for decision-making in such a volatile, low-quality environment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.177937 |
| AutoETS | 0.178215 |
| MSTL | 0.359979 |
| AutoARIMA | 1.655842 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 22% |
| H-stat | 5.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.895 |
| Excess Kurtosis | -0.18 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.295 |
| Market Cap | 11,935,760 |
| Beta | 0.11 |
| Previous Name | Aspire BioPharma, Inc. |
| Website | https://aspirebiolabs.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.64086956 |
| Address1 | 23,150 Fashion Drive |
| Address2 | Suite 232 |
| All Time High | 632.0 |
| All Time Low | 0.11 |
| Ask | 10.88 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 25,260 |
| Average Daily Volume3 Month | 279,085 |
| Average Volume | 279,085 |
| Average Volume10Days | 25,260 |
| Beta | 0.111 |
| Bid | 6.27 |
| Bid Size | 2 |
| Book Value | 9.078 |
| City | Estero |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.51 |
| Current Ratio | 7.986 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 8.7 |
| Day Low | 8.07 |
| Display Name | Aspire Biopharma |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | -2.369 |
| Enterprise Value | -231,373 |
| Eps Trailing Twelve Months | -6.86 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.8564 |
| Fifty Day Average Change | 1.6536002 |
| Fifty Day Average Change Percent | 0.24117616 |
| Fifty Two Week Change Percent | -64.08695 |
| Fifty Two Week High | 23.48 |
| Fifty Two Week High Change | -14.969999 |
| Fifty Two Week High Change Percent | -0.6375639 |
| Fifty Two Week Low | 0.11 |
| Fifty Two Week Low Change | 8.400001 |
| Fifty Two Week Low Change Percent | 76.36364 |
| Fifty Two Week Range | 0.11 - 23.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,649,683,800,000 |
| Float Shares | 1,118,146 |
| Free Cashflow | 7,431,185 |
| Full Exchange Name | NasdaqCM |
| Fullday Change | 0.22 |
| Fullday Change Percent | 2.6538 |
| Fullday Price | 8.51 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.25038 |
| Gross Profits | -24,452 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.201 |
| Held Percent Institutions | 0.03365 |
| Implied Shares Outstanding | 1,402,557 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,768,521,600 |
| Last Split Factor | 1:40 |
| Long Business Summary | Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida. |
| Long Name | Aspire Biopharma Holdings, Inc. |
| Market | us_market |
| Market Cap | 11,935,760 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1860544308 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -11,049,261 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 11,571,095 |
| Open | 8.07 |
| Operating Cashflow | -7,185,846 |
| Operating Margins | -38.80584 |
| Payout Ratio | 0.0 |
| Phone | 908 987 3002 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 8.51 |
| Post Market Time | 1,787,959,806 |
| Prev Name | Aspire BioPharma, Inc. |
| Previous Close | 8.29 |
| Price Hint | 2 |
| Price To Book | 0.93743116 |
| Price To Sales Trailing12 Months | 122.21874 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.216 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.22 |
| Regular Market Change Percent | 2.6538 |
| Regular Market Day High | 8.7 |
| Regular Market Day Low | 8.07 |
| Regular Market Day Range | 8.07 - 8.7 |
| Regular Market Open | 8.07 |
| Regular Market Previous Close | 8.29 |
| Regular Market Price | 8.51 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 21,467 |
| Return On Assets | 0.60576 |
| Return On Equity | -10.32142 |
| Revenue Per Share | 0.295 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,402,557 |
| Shares Percent Shares Out | 0.0471 |
| Shares Short | 66,082 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 118,303 |
| Short Name | Aspire Biopharma Holdings, Inc. |
| Short Percent Of Float | 0.047399998 |
| Short Ratio | 1.44 |
| Source Interval | 15 |
| State | FL |
| Symbol | ASBP |
| Total Cash | 12,167,136 |
| Total Cash Per Share | 8.675 |
| Total Debt | 0 |
| Total Revenue | 97,659 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.86 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.80956 |
| Two Hundred Day Average Change | 4.7004404 |
| Two Hundred Day Average Change Percent | 1.2338538 |
| Type Disp | Equity |
| Volume | 21,467 |
| Website | https://aspirebiolabs.com |
| Zip | 33,928 |